Oligomerix, Inc

Description

• Oligomerix® is a highly differentiated biopharmaceutical company discovering and developing novel therapeutics for Alzheimers disease (AD) and related neurodegenerative diseases such as chronic traumatic encephalopathy (CTE) caused by head injury. Founded in 2006, the Company has developed two programs that target tau oligomers, the small aggregates of tau protein that are implicated in the spread of pathology and the impairment of memory formation in neurodegenerative disease. A function of tau protein (monomer) is to maintain the structure of neurons necessary for the transmission of signals between neurons. In AD, tau loses its normal function when it forms oligomers and acquires proteolytic activity. Small molecule inhibitors are being developed to block tau self-association into oligomers, thereby preventing both tau loss of function and gain of toxic function. Antibody biomarkers are being developed to support these approaches that also have potential as immunotherapeutics. A drug-like lead compound is currently being evaluated in vivo in the human tau mouse model of tau aggregation. This blinded study is being performed by Peter Davies, Ph.D., a world renown expert in the study of tau. Follow us on Twitter @oligomerix
• 

  Headquarters:2 Westchester Park Drive , White Plains, New York, United States

  More
• 

  Phone Number: +1 917-912-4088

• 

  Website: https://www.oligomerix.com

• 

  Employees:9

• 

  Revenue:$10 - 50M

• 

  Legal Name:Oligomerix, Inc

• Oligomerix, Inc's Social Media

  
• Is this data correct?

• |  NAICS Code: 541713  |

  Show More